Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1980 Mar;65(3):746–753. doi: 10.1172/JCI109722

Stereoselective Interaction of Phenylbutazone with [12C/13C]Warfarin Pseudoracemates in Man

Robert A O'Reilly 1,2,3,4, William F Trager 1,2,3,4, Catherine H Motley 1,2,3,4, William Howald 1,2,3,4
PMCID: PMC371418  PMID: 7354137

Abstract

To evaluate the interaction of phenylbutazone with racemic warfarin or R,S-(±)-warfarin in man, S-(−)-warfarin or levowarfarin was synthesized with 13C label in the 2-position of the coumarin nucleus and added to [12C]R(+)-warfarin or dextrowarfarin to form a [12C/13C]pseudoracemate of warfarin. In six normal human subjects, a single oral dose of this “cold labeled” pseudoracemate, 1.5 mg/kg body weight, was administered with and without a daily dosage of phenylbutazone, 300 mg orally, beginning 3 d before the warfarin dose and continuing throughout the hypoprothrombinemia. Plasma samples were obtained daily and analyzed for warfarin content and for one-stage prothrombin activity. Unchanged warfarin in the plasma was fractionated by normal-phase, high-pressure liquid chromatography, and the enantiomorphic ratios were determined by chemical-ionization mass spectrometry with pentadeuteriowarfarin as the internal standard. A highly significant augmentation of the hypoprothrombinemia of the pseudoracemate occurred during the phenylbutazone regimen (P < 0.001) compared with pseudoracemic warfarin administered alone. There was a highly significant increase in the plasma clearance of dextrowarfarin (P < 0.01) and a significant decrease in the plasma clearance of levowarfarin (P < 0.05) during the phenylbutazone regimen compared with administration of warfarin alone. It was concluded that phenylbutazone augmented the hypoprothrombinemia of pseudoracemic warfarin stereoselectively by inhibiting the metabolic disposition of the more hypoprothrombinemic levowarfarin, yet reduced the plasma levels of pseudoracemic warfarin by greatly augmenting the metabolic disposition of dextrowarfarin.

Full text

PDF
746

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggeler P. M., O'Reilly R. A. Effect of heptabarbital on the response to bishydroxycoumarin in man. J Lab Clin Med. 1969 Aug;74(2):229–238. [PubMed] [Google Scholar]
  2. Aggeler P. M., O'Reilly R. A., Leong L., Kowitz P. E. Potentiation of anticoagulant effect of warfarin by phenylbutazone. N Engl J Med. 1967 Mar 2;276(9):496–501. doi: 10.1056/NEJM196703022760904. [DOI] [PubMed] [Google Scholar]
  3. Chan K. K., Lewis R. J., Trager W. F. Absolute configurations of the four warfarin alcohols. J Med Chem. 1972 Dec;15(12):1265–1270. doi: 10.1021/jm00282a016. [DOI] [PubMed] [Google Scholar]
  4. Lewis R. J., Trager W. F., Chan K. K., Breckenridge A., Orme M., Roland M., Schary W. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest. 1974 Jun;53(6):1607–1617. doi: 10.1172/JCI107711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Lewis R. J., Trager W. F. The metabolic fate of warfarin: studies on the metabolites in plasma. Ann N Y Acad Sci. 1971 Jul 6;179:205–212. doi: 10.1111/j.1749-6632.1971.tb46900.x. [DOI] [PubMed] [Google Scholar]
  6. Meinertz T., Gilfrich H. J., Groth U., Jonen H. G., Jähnchen E. Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine. Clin Pharmacol Ther. 1977 Jun;21(6):731–735. doi: 10.1002/cpt1977216731. [DOI] [PubMed] [Google Scholar]
  7. Melander A., Wåhlin E. Enhancement of dicoumarol bioavailability by concomitant food intake. Eur J Clin Pharmacol. 1978 Dec 18;14(6):441–444. doi: 10.1007/BF00716387. [DOI] [PubMed] [Google Scholar]
  8. O'REILLY R. A., AGGELER P. M., LEONG L. S. STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: A COMPARISON OF THE PHARMACODYNAMICS OF DICUMAROL AND WARFARIN IN MAN. Thromb Diath Haemorrh. 1964 Apr 15;11:1–22. [PubMed] [Google Scholar]
  9. O'Reilly R. A. Drug interactions involving oral anticoagulants. Cardiovasc Clin. 1974;6(2):23–41. [PubMed] [Google Scholar]
  10. O'Reilly R. A. Interaction of sodium warfarin and disulfiram (antabuse) in man. Ann Intern Med. 1973 Jan;78(1):73–76. doi: 10.7326/0003-4819-78-1-73. [DOI] [PubMed] [Google Scholar]
  11. O'Reilly R. A., Levy G. Pharmacokinetic analysis of potentiating effect of phenylbutazone on anticoagulant action of warfarin in man. J Pharm Sci. 1970 Sep;59(9):1258–1261. doi: 10.1002/jps.2600590909. [DOI] [PubMed] [Google Scholar]
  12. O'Reilly R. A., Nelson E., Levy G. Physicochemical and physiologic factors affecting the absorption of warfarin in man. J Pharm Sci. 1966 Apr;55(4):435–437. doi: 10.1002/jps.2600550420. [DOI] [PubMed] [Google Scholar]
  13. O'Reilly R. A., Welling P. G., Wagner J. G. Pharmacokinetics of warfarin following intravenous administration to man. Thromb Diath Haemorrh. 1971;25(1):178–186. [PubMed] [Google Scholar]
  14. Robinson D. S., Benjamin D. M., McCormack J. J. Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther. 1971 May-Jun;12(3):491–495. doi: 10.1002/cpt1971123491. [DOI] [PubMed] [Google Scholar]
  15. Schary W. L., Lewis R. J., Rowland M. Warfarin-phenylbutazone interaction in man: a long term multiple dose study. Res Commun Chem Pathol Pharmacol. 1975 Apr;10(4):663–672. [PubMed] [Google Scholar]
  16. Tillement J. P., Zini R., Mattei C., Singlas E. Effect of phenylbutazone on the binding of vitamin K antagonists to albumin. Eur J Clin Pharmacol. 1973 Jun;6(1):15–18. doi: 10.1007/BF00561795. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES